Cryptococcosis: Clinical and biological aspects

Medical Mycology

Volumn 38, Issue , 2000, Pages 205-213

  Kwon Chung, K J ^a   Sorrell, T C ^b   Dromer, F ^c   Fung, E ^d   Levitz, S M ^e  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

^c INSTITUT PASTEUR   (France)

^d STANFORD UNIVERSITY   (United States)

^e BOSTON UNIVERSITY   (United States)

Author keywords

Cryptococcus neoformans; Genomics; Immunology

Indexed keywords

AMPHOTERICIN B; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; FLUCYTOSINE; FUNGAL PROTEIN; LYSOPHOSPHOLIPASE; PROTEINASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BIOCHEMISTRY; CLINICAL FEATURE; CONFERENCE PAPER; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; ENZYME ACTIVITY; ENZYME ANALYSIS; EUROPE; FUNGAL GENETICS; GENE SEQUENCE; HEALTH SURVEY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOLOGY; INCIDENCE; MEDICAL RESEARCH; MICROBIOLOGICAL EXAMINATION; NONHUMAN; PROPHYLAXIS; T LYMPHOCYTE; VIRULENCE; WESTERN HEMISPHERE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AIDS-RELATED OPPORTUNISTIC INFECTIONS; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; FEMALE; HUMANS; MALE; MIDDLE AGED; VIRULENCE;

CRYPTOCOCCUS NEOFORMANS VAR. NEOFORMANS; FILOBASIDIELLA NEOFORMANS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0034504814     PISSN: 13693786     EISSN: None     Source Type: Journal    
DOI: 10.1080/mmy.38.s1.205.213     Document Type: Article

References (50)

1. Epidemiology of cryptococcosis in France: 9-year survey (1985-1993)
2. Individual and environmental factors associated with Cryptococcus neoformans serotype D infections in France
3. Prognostic factors in cryptococcal meningitis: A study in 111 cases
4. Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks
5. Comparison of amphotericin B and fluconazole efficacy in the treatment of cryptococcosis in HIV-negative patients: Retrospective analysis of 83 cases
6. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis
7. Cryptococcal disease in patients with the acquired immunodeficiency syndrome. Diagnostic features and outcome of treatment
8. CSF cytokine profiles as markers of meningeal involvement and potential prognostic indicators during cryptococcosis in HIV-infected (HIV +) and-non-infected (HIV-) patients
9. Cytokine profiles of AIDS patients are similar to those of mice with disseminated Cryptococcus neoformans infection
10. Are two Cryptococcus neoformans strains epidemiologically linked?
11. Epidemiological evidence for dormant Cryptococcus neoformans infection
12. Genetic resistance to murine cryptococcosis: Increased susceptibility in the CBA/N X1D mutant strain of mice
13. Putative virulence factors of Candida albicans
14. Phenoloxidase activity and virulence in isogenic strains of Cryptococcus neoformans
15. Catecholamine oxidative products but not melanin, are produced by Cryptococcus neoformans during neuropathogenesis in mice
16. Urease as a virulence factor in experimental cryptococcosis
17. Genetic association of mating types and virulence in Cryptococcus neoformans
18. Cryptococcus neoformans mating and virulence was regulated by G-protein α-subunit GPA1 and cAMP
19. Calcineurin is required for virulence of Cryptococcus neoformans
20. Extracellular proteolytic activity of Cryptococcus neoformans
21. Variants of a Cryptococcus neoformans strain elicit different inflammatory responses in mice
22. A rapid method for detecting extracellular proteinase activity in Cryptococcus neoformans and a survey of 63 solates
23. Identification of extracellular phospholipase B, lysophospholipase and acyl transferase activities in the basidiomycetous fungus Cryptococcus neoformans
24. Purification and characterization of secretory phospholipase B, lysophospholipase and lysophospholipase transacylasc from a virulent train of the pathogenic fungus, Cryptococcus neoformans
25. Development of an ELISA for detection of cryptococcal phospholipase antibodies
26. Phospholipase activity in Cryptococcus neoformans: A new virulence factor?
27. Epidemiologic differences between the two varieties of Cryptococcus neoformans
28. Epidemiology and host and variety-dependent characteristics of infection due to Cryptococcus neoformans
29. Clinical and host differences between infections with the two varieties of Cryptococcus neoformans
30. Presence of α and a mating types in environmental and clinical collections of Cryptococcus neoformans var gattii strains from Australia
31. Heteronuclear NMR studies of metabolites produced by Cryptococcus neoformans in culture media: Identification of possible virulence factors
32. Cryptococcus neoformans resides in an acidic phagolysosome of human macrophages
33. Relationship between protease production and capsule size in Cryptococcus neoformans
34. Biochemical and functional characterisation of secreted phospholipase activities from Cryptococcus neoformans in their naturally occurring state
35. Isolation and characterisation of the phospholipase B gene of Cryptococcus neoformans var. Gattii
36. Dominant selection system for use in Cryptococcus neoformans
37. Characterization of the glyceraldehyde-3-phosphate dehydrogenase gene and the use of its promotor for heterologous expression in Cryptococcus neoformans, a human pathogen
38. Development of a transformation system for C. Neoformans var. Gattii by biolistic transfer of DNA
39. Depletion of CD+ (L3T4+) lymphocytes in vivo impairs murine host defense to Cryptococcus neoformans
40. Idiopathic CD4+ T-lymphocytopenia - Four patients with opportunities infections and no evidence of HIV infection
41. Cryptococcus neoformans
42. Influence of cryptococcal antigens on cell-mediated immunity
43. Serological, electrophoretic, and biological properties of Cryptococcus neoformans antigens
44. T cell response to soluble cryptococcal antigens after recovery from cryptococcal infection
45. Lymphoproliferation and cytokines profiles in human peripheral blood mononuclear cells stimulated by Cryptococcus neoformans
46. Identification of a 105 kilodalton Cryptococcus neoformans mannoprotein involved in human cell-mediated immune response